BioSpace

Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?

By BioSpace

1 min read
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights